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Abstract
Epithelial ovarian cancer (EOC) is the deadliest of the gynecological malignancies, due in part to its clinically occult
metastasis. Therefore, understanding the mechanisms governing EOC dissemination and invasion may provide new targets
for antimetastatic therapies or new methods for detection of metastatic disease. The cAMP-dependent protein kinase (PKA)
is often dysregulated in EOC. Furthermore, PKA activity and subcellular localization by A-kinase anchoring proteins (AKAPs)
are important regulators of cytoskeletal dynamics and cell migration. Thus, we sought to study the role of PKA and AKAP
function in both EOC cell migration and invasion. Using the plasma membrane-directed PKA biosensor, pmAKAR3, and an
improved migration/invasion assay, we show that PKA is activated at the leading edge of migrating SKOV-3 EOC cells, and
that inhibition of PKA activity blocks SKOV-3 cell migration. Furthermore, we show that while the PKA activity within the
leading edge of these cells is mediated by anchoring of type-II regulatory PKA subunits (RII), inhibition of anchoring of either
RI or RII PKA subunits blocks cell migration. Importantly, we also show – for the first time – that PKA activity is up-regulated
at the leading edge of SKOV-3 cells during invasion of a three-dimensional extracellular matrix and, as seen for migration,
inhibition of either PKA activity or AKAP-mediated PKA anchoring blocks matrix invasion. These data are the first to
demonstrate that the invasion of extracellular matrix by cancer cells elicits activation of PKA within the invasive leading
edge and that both PKA activity and anchoring are required for matrix invasion. These observations suggest a role for PKA
and AKAP activity in EOC metastasis.
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Introduction
Epithelial ovarian cancer (EOC) is the fifth most common cause
of cancer deaths in women in the United States and has the
highest mortality rate of all gynecologic cancers [1]. Approxi-
mately 80% of patients present with late stage disease and less than
25% of those women are cured. EOC constitutes the overwhelm-
ing majority (.90%) of ovarian malignancies and is unique in its
clinically occult dissemination and metastasis [2]. In contrast to
most other types of carcinoma, dissemination of EOC through the
vasculature and formation of truly distal metastases is a rare
occurrence. EOC cells shed from the primary tumor on the
surface of the ovary and exfoliate into the peritoneal cavity. The
anatomic placement of the ovaries facilitates local spread of EOC,
which can occur by direct migration and invasion of tumor cells to
and into adjacent organs, as well as through transport of exfoliated
tumor cells throughout the peritoneal cavity by normal peritoneal
fluid flow [2,3]. Because of this unique and furtive mode of
dissemination, efforts in developing methods for early detection of
EOC have been largely unsuccessful [4,5,6]. Despite cytoreductive
surgery, combination chemotherapies and strategies for determin-
ing serum biomarkers, local and disseminated chemoresistant cells
persist and eventually flourish, leading to the high recurrence and
,25% five-year survival rate of patients with EOC [3,5,7,8,9].
Thus, a better understanding of the cellular and molecular
mechanisms governing EOC dissemination and invasion has the
potential to have significant impact on the course of the disease.
Due to the dependence of EOC dissemination and metastasis
on cellular migration and invasion, our laboratory has endeavored
to understand the mechanisms underlying these processes in EOC.
Cell migration is a highly ordered process that requires
coordinated effort between numerous proteins in distinct subcel-
lular regions [10,11,12]. We have previously shown that the
cAMP-dependent protein kinase (PKA) is important for cell
migration and leading edge dynamics in a number of cells
[13,14,15]. PKA is a heterotetrameric kinase that can exist in two
isoforms, type-I and type-II, depending on the isoform of
regulatory (RI and RII) subunit associated with the holoenzyme.
PKA has numerous targets associated with actomyosin based cell
movement [16] and early studies showed that hyper-activation or
inhibition of PKA inhibited chemotactic cell migration [16,17,18].
This seemingly contradictory role for PKA was clarified by the
demonstration that, in addition to overall activity, localization of
PKA in subcellular space, mediated through the binding of PKA
R subunits to A kinase anchoring proteins (AKAPs; [19,20]),
regulates cell migration [13,21,22]. Specifically, it has been shown
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structures at the leading edge of migrating cells [13,21,22].
Moreover, broad inhibition of type-I and type-II anchoring (i.e.
anchoring through RI or RII subunits) in general [13,21], or
specific inhibition of individual anchoring proteins (e.g. AKAP-
Lbc; [22]), inhibits migration. These and other reports (reviewed
in [23,24]), establish the importance of localizing PKA activity to
distinct subcellular locations during normal cell migratory
processes.
Underscoring the potential importance of PKA in ovarian
cancer pathogenesis are the observations that PKA activity and
subunit expression are often dysregulated in EOC. Expression of
the PKA catalytic subunit [25] and regulatory RI subunit
[26,27,28] correlates with advanced stage and/or more aggressive
EOC. Moreover, the mRNA levels of AKAP3 (aka AKAP110 or
fibrous sheath protein of 90 kDa (FSP90)) in ovarian tumors
positively correlate with disease stage and poor prognosis [29,30],
while two other AKAPs – AKAP1 (aka AKAP149) and AKAP13
(aka AKAP-Lbc) – also appear to be up-regulated in mucinous
EOC (A. Howe, unpublished observations from Oncomine).
Despite these observations, the functional significance PKA and
AKAP signaling in metastatic EOC cells has not been well
investigated.
Given the importance of PKA and AKAP function for cell
migration and their dysregulation in EOC, we investigated the
spatial regulation of PKA activity in migrating EOC cells and
determined whether PKA activity and anchoring are required for
EOC cell migration. Here, we report that PKA activity is up-
regulated in the leading edge of EOC cells not only during
migration but also during extracellular matrix invasion, as well.
Further, inhibition of PKA activity and AKAP function blocks
EOC cell migration and invasion. These observations demon-
strate, for the first time, the importance of PKA anchoring for
matrix invasion and establish the importance of spatially regulated
PKA activity in the migration and invasion – and thus perhaps
metastasis – of EOC cells.
Materials and Methods
Reagents and Cell Culture
SKOV-3 and COS-7 cells were obtained from American Type
Culture Collection and maintained in antibiotic-free Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% (vol/
vol) fetal bovine serum (FBS). HIO-80 cells were a generous gift
from Dr. Andrew Godwin (Department of Molecular Oncology,
Fox Chase Cancer Center) and were maintained in a 1:1 mixture
of antibiotic-free Medium 199:MCDB-105 supplemented with 4%
FBS and 0.2 U/ml porcine insulin. All cells were grown at 37uCi n
a humidified incubator containing 5% CO2. DMSO, cytochalasin
D and trypan blue were purchased from Sigma-Aldrich (St. Louis,
MO). GM6001 was obtained from Millipore (Billercia, MA).
Phenol red-free Matrigel and human fibronectin were acquired
from BD Biosciences (Bedford, MA). Pharmacological inhibition
of PKA activity was achieved using H89 or mPKI (Biomol). H89 is
an isoquinolone that competes with ATP for binding to PKA;
despite widespread use and considerable potency, it exhibits only
modest specificity for PKA [31]. mPKI, a highly-specific PKA
inhibitor, is a myristoylated, cell-permeable peptide comprising the
inhibitory pseudo-substrate region (amino acids 14-27) of the
endogenous Protein Kinase A Inhibitor protein (PKI) [14].
Pharmacological inhibition of PKA anchoring was achieved using
StHt31 (Promega), a stearated peptide comprising the PKA R-
subunit binding domain from Ht31 (aka AKAP-Lbc); thus, StHt31
acts as a cell-permeable competitive inhibitor of the interaction
between endogenous AKAPs and both RII and, at somewhat
higher concentrations, RI PKA subunits [32,33]. Genetic
inhibitors of PKA activity and of type-I or type-II PKA anchoring
are described below.
Plasmids and Transfection
The plasmid encoding mCherry-fused to the PKA inhibitor
protein PKI (see above) has been described previously [14], while
plasmids encoding GFP fused to the type-I or type-II anchoring
inhibitors (RI anchoring disrupter (RIAD; [34]) and superAKAP-
in silico (sAKAPis; [32], respectively), as well as their corresponding
scrambled (scr) negative controls, were generated using the 59
phosphorylated oligonucleotides (Invitrogen) listed in Table S1.
Specifically, complementary oligos were annealed, generating 59
SalI and 39 BamHI sticky ends, then ligated directly into SalI/
BamHI-digested pEGFP-C1 (Clontech). mCherry versions of
RIAD and sAKAPis were generated by replacing the NheI-BamHI
fragment encoding EGFP in the respective plasmids with the NheI-
BamHI fragment from pmCherry-C1. For transfection and
transient expression of proteins, cells were transfected using
Fugene6 (Roche) according to the manufacturer’s protocol.
Briefly, 6 ml of Fugene6 was added to 100 ml serum and antibiotic
free DMEM, briefly vortexed, and incubated at room temperature
for 5 min. A total of 1.5 mg DNA was added to the mixture, briefly
vortexed, and incubated at room temperature for 15 min. The
mixture was then added drop-wise to a 35 mm dish containing
cells at between 80-90% confluence, allowed to stand at RT for 2-
3 min, then returned to the incubator. All experiments were done
between 24-48 h after transfection.
Immunofluorescence
For visualization of actin, fibronectin, paxillin, and PKA RIa
and RIIa subunits, cells were fixed in 3.7% formaldehyde in PBS
for 10 min, permeabilized for 10 min in PBS containing 0.25%
triton 6100, blocked with PBS containing 3% BSA either for 1 h
at RT or overnight at 4uC then incubated with anti-fibronectin
(1:400, BD Transduction), anti-paxillin (1:500, BD Transduction),
anti-PKA RIa or RIIa (Genetex 1:200 and BD Transduction
1:200 respectively) primary antibodies for 1 h at RT. After
washing 365 min with PBS, cells were incubated with Alexa-594
coupled donkey anti-mouse secondary antibody (Invitrogen, 1:400)
and Alexa-488 conjugated phalloidin (Invitrogen, 1:100) for 1 h at
RT. Coverslips were mounted onto glass microscope slides (Fisher)
using a small volume of PermaFluor mountant (Thermo
Scientific). Epifluorescence images were captured though 10, 20,
40, and 60X Plan Apo objectives on a Nikon Eclipse TE-2000E
inverted microscope using the appropriate fluorophore-specific
filters (Chroma Technology Corp, Rockingham, VT) and a
CoolSnap HQ camera (Photometrics, Tucson, AZ) controlled by
Elements (Nikon) software.
Wound-healing migration assay
Glass coverslips were sterilized by consecutive soaking in 30 min
intervals in increasing concentrations (70, 95, 100%) of EtOH.
The coverslips were removed from EtOH and air-dried in the
tissue culture hood. Once dried, the sterile coverslips were coated
in 20 mg/ml human fibronectin diluted in sterile PBS either
overnight at 4uCo r2ha t3 7 uC. A confluent monolayer of cells
was seeded onto ECM conjugated coverslips and allowed to
adhere overnight. A wound was made in the monolayer by
scraping a sterile p200 pipette tip across the cells, and the
coverslips were washed once with sterile PBS to remove any cell
debris. Images were acquired using a 10x Plan Apo objective on
PKA and AKAPs in Ovarian Cancer Cell Migration
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above.
Trypan Blue Exclusion Assay
To assesscell viability, a 1:1mixture of trypan blue (0.4%, Sigma)
and serum free medium containing 1% BSA was added to the cells
and incubated at room temperature for 10 min immediately after
either removing the donut or creating the wound in the monolayer.
Images were taken of the periphery of the donut and along the
entire margin of the wound using a 10X Plan Apo objective on the
Nikon Eclipse TE-2000E as previously described.
Fabrication of silicone gaskets
Forty g of Sylgard 184 silicone elastomer (Ellsworth Adhesives)
and 4 g of Sylgard 184 elastomer curing agent were rigorously
mixed until cloudy with bubbles. The cloudy mix was poured into
a sterile 10 cm tissue culture dish to a depth of 2-4 mm in height.
Bubbles were removed by placing the dish in an 850 ml Desi-Vac
container (Fisher) and evacuating the chamber 60 times and
allowing the chamber to stand for 10 min. This step was repeated
twice or until the mixture was free of bubbles. The silicone mixture
was allowed to cure at room temperature for 48 hrs or for an hour
on an 84uC hot plate until completely polymerized. The silicone
template was gently removed from the dish and placed on a clean
dry surface suitable for cutting. To fabricate the donut-shaped
gasket, a 6 mm biopsy punch was used to generate a silicone
cylinder, and a 2 mm biopsy punch was used to make a smaller
hole in the center of the 6 mm cylinder. The silicone ‘‘donuts’’
were then washed in Liquinox (diluted 1:10 in nanopure water) for
15 min, rinsed 10 times with nanopure water, washed with 70%
EtOH for 15 min, then stored in fresh 70% EtOH until needed.
Donut Migration/Invasion Assay
Sterile glass coverslips were coated with 20 mg/ml fibronectin as
described above. Clean, sterile silicone donuts were allowed to air
dry before placing onto the coated coverslips. A change in
refraction at the donut-coverslip interface can be seen as the donut
adheres by conformal contact. Subconfluent cells were serum-
starved the night before the assay. The cells were trypsinized and
resuspended in the appropriate serum free medium containing 1%
BSA and counted using a hemocytometer. Cells were plated at
confluence (6000 cells/donut for SKOV-3, COS-7, and HIO-80)
in a 10 ml volume using a sterile gel-loading tip into the center of
the donut-shaped gasket so as to contain them within a confined
area. The number of cells required to form a confluent monolayer
depends on the ECM chosen, the diameter of the inner well of the
donut, and the spreading ability of the cells, and thus needs to be
determined empirically for each cell line. Sterile PBS was added
around the gasket to prevent evaporation of the small volume of
media. After adhering overnight, the PBS was aspirated, and the
donuts were carefully removed using sterile forceps. The nuclei
were stained using Hoescht 33342 nuclear stain (Invitrogen,
1:2000 in media) for 15 min at 37uC. The staining media was
removed and replaced with either complete media or media
containing pharmacologic agents as described in the figure
legends. For invasion assays, the Hoescht-stained monolayer was
overlaid with phenol-red free Matrigel and incubated for 15 min
at 37uC to allow polymerization. The embedded cells were then
supplemented with complete or treated media as in the migration
assay. Initial images were acquired through a 2X PlanApo
objective on a Nikon Eclipse TE-2000E inverted microscope as
described above. Cells were either treated with 10 ng/ml EGF or
high serum (10%) to stimulate migration. Additional images were
acquired after the indicated times and initial and final state image
pairs were analyzed using the default settings of a custom written
ImageJ macro (DonutQuant available as Text S1). Briefly, the
macro centers and thresholds both initial and final state images
then removes far-outlier cells, i.e. cells outside the circular
monolayers that are too far to be attributable to migration (e.g.
cells that have loosened and floated in from another area of the
dish). A mask of the centered, initial image is then created and
superimposed on the final state image and all of the nuclei outside
the border of the initial image mask are counted as migrated cells.
FRET Imaging
SKOV-3 cells expressing the PKA activity biosensor, pmA-
KAR3 [35,36] were rinsed and maintained in Leibovitz L-15
medium for FRET imaging. Cells were imaged on a Nikon Eclipse
TE-2000E microscope with a 606/1.4 NA Plan Apo oil-
immersion objective lens and cooled CCD camera. CFP, YFP
and FRET images were acquired 10 hrs after the start of the assay.
The acquisition was set with 700 ms exposure and 262 binning
for all three acquisitions. Images in each channel were subjected to
background subtraction, and ratios of yellow-to-cyan color were
calculated using the FRET Analyzer ImageJ plugin. Pseudocolor
images were generated using the ImageJ ‘Ratio’ look up table.
Images were background-subtracted using the ‘‘Subtract back-
ground’’ feature in ImageJ, with a rolling ball radius of 500.
Results
PKA activity is increased at the leading edge of randomly
migrating SKOV-3 cells
Previous work had demonstrated discrete activation of PKA in
the migratory leading edge of many [13,21,22] but not all [37] cell
types. To determine if PKA was activated at the leading edge of
migrating EOC cells, SKOV-3 human EOC cells were transfected
with pmAKAR3, a plasma membrane-directed FRET biosensor
for PKA activity [21,36], then plated on FN-coated glass
coverslips, stimulated with 10 ng/ml EGF for 4-6 hrs (to promote
random, chemokinetic migration), and monitored by live-cell
imaging. PKA activity (as indicated by elevated FRET ratios) was,
indeed, discretely and dynamically elevated within the leading
edge of migrating SKOV-3 cells (Figure 1 and Movie S1). This
Figure 1. PKA is activated at the leading edge of migrating
SKOV3 cells. SKOV-3 cells were transfected with pmAKAR3, plated
onto fibronectin-coated dishes overnight, stimulated with 10 ng/ml
EGF for 4-6 h, and then imaged by FRET microscopy. Images were
captured every 30 sec, then pseudocolored according to FRET ratio
(color scale shown in frame 09): this montage depicts frames 2 min
apart. For the whole sequence, see Video S1. Scale bar =5 mm.
doi:10.1371/journal.pone.0026552.g001
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regulating leading edge dynamics, and thus the migration of
actively migrating EOC cells. This hypothesis was supported by
early, exploratory experiments in which SKOV-3 cells were
subject to wound-healing or scratch migration assays in the
absence or presence of widely used inhibitors of PKA activity (H89
and mPKI; see Materials and Methods)) and anchoring (StHt31;
see Materials and Methods). Examination of cell morphology
shortly after the start of these assays showed significant effects of
these inhibitors on leading edge morphology and migration
(Figure S1). Specifically, untreated cells migrated into wounded
areas efficiently and with broad, ruffling lamellipodia (Figure S1A
and D). In contrast, cells in which PKA activity was inhibited with
the non-selective PKA inhibitor H89 or the highly-selective
inhibitor mPKI did not migrate efficiently and barely entered
the wound space, exhibiting leading edge structures devoid of
ruffles but rife with focal adhesions – evoking an adhesive,
spreading phenotype more than one of migration (Figure S1B and
D). Cells in which PKA anchoring was disrupted by StHt31
entered the wound space to a greater extent than H89- or mPKI-
treated cells but, unlike control cells, exhibited multiple,
erratically-spaced ruffling edges per cell (Figure S1C and D).
Together, these results further supported the hypothesis that EOC
cell migration might require PKA activity and anchoring and
warranted further investigation using more sophisticated ap-
proaches and specific reagents.
EOC cell migration is regulated by activity and anchoring
of PKA
Wound-healing migration assays, while inexpensive and easy to
implement, suffer from several limitations, not the least of which
are fatal injury to cells along the assay front and removal of the
underlying extracellular matrix (ECM). Thus, an experimental
condition that results in inefficient migration in this assay may
reflect, for example, heightened sensitivity to bystander damage or
failure to produce de novo matrix on which to migrate. Therefore,
to further and better explore the requirement of PKA activity and
anchoring specifically for EOC cell migration, we developed an
improved version of a previously described migration assay [38]
that easily and accurately measures the number of cells migrating
in a radial manner from a defined circular monolayer (Figure 2;
see Materials and Methods for details). Our assay – coined the
‘donut assay’, after the donut-shaped silicone gaskets used to
establish the monolayer – is reliable, inexpensive, easy to
implement, applicable to nearly any cell type, and scalable to
achieve relatively high throughput and statistical significance using
a small number of cells (,6000), relative to other comparable
‘release’ assays (e.g. wound-healing assays). In addition, unlike
wound-healing assays, our approach significantly reduces both the
denuding of the ECM protein covering the migration surface
(Figure S2) and the fatal injury to cells on the assay periphery
(Figure S3). To increase the utility and ease of implementation of
the assay, we developed an ImageJ macro (‘DonutQuant’; see Text
S1) to quickly and automatically quantify migration. Briefly, the
macro subtracts an initial, ‘time=0’ image (taken immediately
after donut removal) from a later or final image and counts the
nuclei outside the ‘time=0’ area (Figure 2C and D). Experiments
using cytochalasin D to inhibit actin dynamics (Figure 2C and D)
as well as mitomycin C to inhibit cell cycle progression (data not
shown) have confirmed that the assay measures migration and not
simply displacement of the monolayer by cell division. We have
used this assay to measure migration in a wide variety of cell types
(including CHO-K1, COS7, HIO-80, HUVEC, MCF7,
MCF10A, MDA-MB-231, MDCK, NIH3T3, REF52, and
SKOV-3) with comparable ease and effect (A. McKenzie, S.
Campbell, A. Howe, unpublished observations).
Using this assay, we investigated the effects of inhibiting PKA or
AKAP function on EOC cell migration by transfecting SKOV-3
cells with plasmids encoding fluorescent proteins (EGFP,
mCherry) fused to peptide inhibitors of PKA activity or anchoring
(see Materials and Methods). Specifically, we used the fluorescent
protein mCherry fused to the PKA inhibitor protein PKI
(mCherry-PKI) to inhibit PKA activity [14], and EGFP fused to
the RI anchoring disruptor (RIAD) [34] and superAKAPis
(sAKAPis) [32] peptides to specifically disrupt type-I and type-II
PKA anchoring, respectively. Plasmids encoding mCherry alone
or EGFP fused to scrambled RIAD or sAKAP is sequences were
used as negative controls. These genetically encoded reagents
allow exquisite specificity in the inhibition of PKA activity [14] or
inhibition of anchoring through both RI and RII subunits [32,34]
while enabling the detection and monitoring of treated cells
through fluorescence microscopy. Distinguishing between type-I
and type-II anchoring is appropriate and necessary, as type-I and
type-II PKA activity can regulate distinct signaling pathways
[19,20] and, while both types of PKA have been implicated in
migration in other systems [13,21-23,39], neither have been
assessed in the context of ovarian cancer migration.
After transfection, cells were subjected to the donut migration
assay and, after 24 hrs, the number of transfected cells that
migrated, as well as the total number of transfected cells and total
number of migrated (transfected and non-transfected) cells was
quantified (Figure 3). Acquisition of these three numbers allows the
expression of migration as the percentage of migrated, transfected
cells over the total migrated cells (‘MX/TM’) or, to control for
differences in transfection efficiency between plasmids, the
percentage of migrated, transfected cells over the total number
of transfected cells (‘MX/TX’). Using this method, SKOV-3
migration was significantly attenuated when either PKA activity
(Figure 3A and B) or anchoring (Figure 3C) was inhibited using the
genetic reagents described above. Interestingly, migration was
inhibited almost equally by disruption of anchoring through either
RI or RII subunits (Figure 3C), consistent with previous reports
establishing the importance of both type-I and type-II PKA
anchoring in the migration of other cell types [13,21,22,39]. In
summary, these data establish the necessity of PKA activity and
anchoring for the migration of EOC cells.
Type-II PKA is responsible for leading edge PKA activity
during migration
Given that PKA activity was enriched in the leading edge of
migrating SKOV-3 cells and that inhibition of PKA activity and
anchoring through both RI and RII stunted migration, we sought
to determine whether leading edge PKA activity was mediated
through either type-I or type-II anchoring. To assess the effect of
RI- or RII-AKAP anchoring disruption on the localization of PKA
activity during EOC migration, SKOV-3 cells were co-transfected
with pmAKAR3 and plasmids expressing genetic inhibitors of
type-I and type-II R-subunit anchoring (RIAD and sAKAPis,
respectively) fused to mCherry. The mCherry fluorescence spectra
does not overlap with those of either YFP or CFP and thus allow
these fluorescently-labeled anchoring disruptors to be used in
conjunction with FRET microscopy. Once transfected, the cells
were subject to the donut migration assay for 10 hrs where upon
the cells were imaged via FRET microscopy as described above.
Cells expressing both the anchoring disruptor and PKA reporter
transfected plasmids were imaged and CFP, YFP, FRET, and
mCherry images were acquired. To quantify the percentage of
cells exhibiting leading edge PKA activity, the average FRET ratio
PKA and AKAPs in Ovarian Cancer Cell Migration
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the cell) was measured in proportion to the FRET ratio in the
cytoplasm (FRETcyto; measured 25-50 mm from the front of the
cell (Figure 4E)). Ratio values were binned into high (FRETLE/
FRETcyto $1.5), moderate (FRETLE/FRETcyto between 1.2 and
1.5), and no (FRETLE/FRETcyto ,1.2) leading edge PKA activity.
Using these strict parameters .80% of cells expressing pmAKAR
in addition to mCherry-sAKAPis scr, -RIAD, or -RIAD scr
showed leading edge PKA activity (Figure 4A, C, D, F and G).
However, ,30% of the cells co-expressing pmAKAR3 and
mCherry-sAKAPis showed leading edge PKA activity (Figure 4B,
F and G). In these instances, the average FRET ratio was
significantly lower than that seen in sAKAPis scr controls cells
(Figure 4F). Additional observations obtained by immunofluores-
cent staining of migrating SKOV-3 cells with antibodies against
RI and RII PKA subunits revealed a clear enrichment of RII, but
not RI, in protrusive leading edge structures (Figure S4), consistent
with observations in other cell types [13,22]. These data, in
conjunction with the migration data reported above, demonstrate
that PKA is localized to the leading edge of migrating EOC cells
and that PKA activity is required for EOC cell migration.
Furthermore, though leading edge PKA activity seems to be
mediated by RII-AKAP interactions, our data demonstrate a
requirement for both RI and RII anchoring in cell migration.
Type-II PKA mediates leading edge PKA activity at the
invading front of SKOV-3 EOC cells
Late-stage EOC is characterized by disseminated intraperito-
neal metastases that form as a consequence of localized invasion of
the submesothelial ECM [2,40]. Invasion through a three-
dimensional matrix is a highly ordered process that is unique in
both mode and mechanism of action from two-dimensional
migration [41,42,43,44]. Importantly, the localization of PKA
activity and role of PKA anchoring in cancer cell invasion have
never been directly investigated. Thus, to assess whether PKA
activity and AKAP function were required for EOC cell invasion,
as well as migration, we modified our migration assay to measure
invasion by overlaying cell monolayers, immediately after donut
removal, with Matrigel - a basement membrane extract commonly
used in invasion assays (Figure 5A). While similar approaches have
been taken with other chemokinetic migration/invasion assays
[45], initial experiments were performed to ensure that this
modification assessed true invasion. Specifically, donut migration
and invasion assays using the HIO-80 human immortalized
ovarian epithelial cell line [46] showed that these non-trans-
formed, non-tumorigenic cells migrate efficiently on a two-
dimensional ECM, but are incapable of navigating through the
three-dimensional Matrigel overlay (Figure 5B). In contrast,
metastatic SKOV-3 cells exhibited readily-detectable migration
through the Matrigel overlay (Figure 5C). As expected, the
efficiency of movement through the three-dimensional ECM was
lower than across a two-dimensional surface, consistent with an
increased ‘barrier’ function attributable to the Matrigel. Further-
more, inhibition of matrix metalloproteinases (MMPs) with
GM6001 significantly reduced the ability of SKOV-3 cells to
invade through the Matrigel (Figure 5C), suggesting that the
movement of cells was indeed due to invasion rather than simply
migration under the Matrigel. Unexpectedly, while GM6001
inhibited invasion, it also significantly enhanced the migration of
SKOV-3, but not HIO-80 cells (Figure 4B and C); we have found
Figure 2. A modified radial migration assay – the Donut assay. (A) A schematic representation of the donut migration assay in which cells are
seeded at confluence on an extracellular matrix-coated glass coverslip within a donut-shaped silicone gasket. After the cells have stably adhered, the
gasket is removed, allowing the cells to migrate radially. Images of the monolayer are captured immediately after donut removal and at any time
point thereafter that is suitable to allow migration of a given cell line. A custom ImageJ macro uses the initial image as a subtractive mask to
determine the number of migrated cells in the final image taken at the end of the assay. Details are given in Materials and Methods. (B) A picture of
five donut gaskets on a single 25 mm coverslip; this allows facile setup of replicate assays to increase throughput and generate statistically significant
data. (C) COS-7 cells were subject to the donut migration assay in the presence of 2 mM cytochalasin D (cytoD) or DMSO as a vehicle control.
Representative images taken at the beginning (0 h) and end (20 h) of the assay, as well as masked (final minus initial) images depicting migrated cells
are shown. (D) The number of migrated COS-7 cells was calculated using the ImageJ macro as described in Materials and Methods. Data represent
the mean 6 S.E. of five donuts per coverslip with three separate coverslips per treatment. (*=P,0.001).
doi:10.1371/journal.pone.0026552.g002
PKA and AKAPs in Ovarian Cancer Cell Migration
PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26552no precedent and currently have no explanation for this. Finally,
the performance of our assay was comparable to or better than
that seen with a traditional modified Boyden chamber/Trans-
well
TM invasion assay; while SKOV-3 cells showed comparable
invasive potential, the non-invasive HIO-80 cells also showed low
but significant ability to navigate through Matrigel-coated
Transwell
TM membranes in our hands (data not shown). Taken
together, these observations validate this new method as an
effective assay to measure tumor cell invasion.
To assess the localization of PKA activity during EOC cell
invasion, we transfected SKOV-3 cells with the pmAKAR3 PKA
biosensor, subjected them to the donut invasion assay as described
above, and acquired FRET images of invasive cells on the assay
periphery 18 h after Matrigel overlay (Figure 6). Cursory
microscopic analysis of invasive cells revealed elongated morphol-
ogies with narrower leading edge structures (compare Figure 6A-D
to Figure 1 and Figure S2), often containing multiple filopodia
(Figure 6C and D); morphologies consistent with three-dimen-
sional invasion compared to two-dimensional migration. Impor-
tantly, the vast majority of invasive cells exhibited either discrete or
broad areas of increased PKA activity within their invasive leading
edges (Figure 6A-D). To quantify the percentage of cells exhibiting
invasive edge PKA activity, the average FRET ratio at the invasive
leading edge was measured in proportion to the FRET ratio in the
cytoplasm as described for Figure 4. Greater than 80% of the
imaged cells displayed an increase in PKA activity in invading
edge (Figure 6F). Leading-edge, as well as and global PKA activity
was all but eliminated by co-expression of pmAKAR3 with
mCherry-PKI, confirming the specificity of the pmAKAR reporter
for PKA activity in this assay (Figure S5). Given that invasion often
utilizes different mechanisms of motility than does 2D migration,
we sought to determine whether the anchoring mechanism driving
PKA activity at the invasive leading edge was fundamentally
different than that seen for the migrating leading edge. Thus, in
parallel to the experiments depicted in Figure 4, SKOV-3 cells
expressing pmAKAR3 and fluorescent inhibitors of type-I or type-
II PKA anchoring (mCherry-RIAD or mCherry-sAKAPis,
respectively) were subject to the donut invasion assay and analyzed
by FRET microscopy as described above. The vast majority
(,80%) of cells expressing RIAD or non-inhibitory control
peptides for RIAD and sAKAPis displayed discrete areas of
heightened PKA activity at the invasive leading edge (Figure 7A,
C, D and E), while only ,10% of cells expressing sAKAPis
displayed significant leading edge PKA activity (Figure 7B and E).
These data establish – for the first time – that matrix invasion, like
migration, also invokes up-regulation of PKA activity at the
leading edge and that this localization is mediated through
anchoring of the PKA RII subunit.
EOC cell invasion requires PKA activity and anchoring
The previous observations demonstrated that PKA was
activated at the leading edge of EOC cells during matrix invasion.
Figure 3. PKA activity and anchoring are required for SKOV-3 cell migration. (A) SKOV-3 cells were transfected with either empty mCherry
plasmid or mCherry-PKI, then subject to donut migration assays. Representative thresholded images of the migrated cells (Migrated, with nuclei
pseudocolored green), the total population of transfected cells (Transfected), and an overlay of these two images are shown. Insets depict
enlargements of the areas indicated by the squares in the top panels. Thus, the total migrated cells (‘TM’) are depicted in green, the total transfected
cells (‘TX’) are depicted in red, and the yellow nuclei depict transfected cells that migrated, i.e. migrated and transfected cells (‘MX’). (B) For cells
transfected with either empty mCherry (mCh) or mCherry-PKI (PKI), the average percent (6 S.E.) of migrated transfected cells over the total number of
migrated cells (‘MX/TM’) was calculated. To normalize for transfection efficiency, average percent (6 S.E.) of migrated transfected cells over the total
number of transfected cells (‘MX/TX’) was also calculated. (*=P,0.05) (C) SKOV-3 cells were transfected with plasmids encoding EGFP fused to
inhibitors of type-I (RIAD) or type-II (sAis) PKA anchoring, or their respective scrambled controls (RIAD scr, sAis scr), then subject to donut migration
assays and analysis as described in (A and B). (**=P,0.001)
doi:10.1371/journal.pone.0026552.g003
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conjunction with pmAKAR3 were subject to the donut migration assay for 10 hr and imaged via widefield fluorescent microscopy and FRET
microscopy. Representative pseudocolored FRET images of cells co-expressing mCherry fused to (A) scrambled superAKAPis (sAKAPis scr), (B)
superAKAPis (sAKAPis), (C) scrambled RIAD (RIAD scr), or (D) RIAD are shown. White arrow heads point to leading edge PKA activity. Scale
bar=10 mm. (E) To quantify the percent of cells exhibiting leading edge PKA activity, the cells were divided into leading edge, cytoplasmic, right and
left quadrants, and a ratio of the FRET ratio values was generated via linescan analysis through the highest intensity pixels within the leading edge.
(F) The tabulated results of cells exhibiting leading edge PKA activity is shown as the percentage of cells displaying low (#1.19), medium
(1.2,x,1.5), or high ($1.5) LE/Cyto FRET ratios. (G) shows a graphical representation of the tabulated data where cells are scored as having leading
edge PKA activity if the LE/Cyto FRET ratios are .1.2 (n=15 from three separate experiments).
doi:10.1371/journal.pone.0026552.g004
Figure 5. A modification of the donut assay allows measurement of matrix invasion. (A) A schematic representation depicting the donut
invasion assay. After removal of the silicone gasket, the cell monolayer is covered with a Matrigel overlay, and invasion is analyzed as described for
Figure 2. (B, C) Migration and Matrigel invasion of non-tumorigenic human immortalized ovarian (HIO-80) epithelial cells (B) and tumorigenic SKOV-3
(C) was assessed at 24, 36, and 48 h after donut removal, in the presence or absence of the matrix metalloprotease inhibitor GM6001 (25 mM). Graphs
represent the mean 6 S.E. of the number of migrated or invaded cells. (*=P,0.05)
doi:10.1371/journal.pone.0026552.g005
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required for invasion, SKOV-3 cells were transfected with
pmCherry-PKI, pEGFP-sAKAPis or pEGFP-RIAD (as described
for Figure 3) and subjected to the donut invasion assay (as
described in Figure 5) for 24 h. As observed for migration,
inhibition of PKA activity and type-II PKA anchoring significantly
attenuated SKOV-3 cell invasion (Figure 8A and B, white & black
bars). Initial analysis of the effect of inhibition of type-I PKA
anchoring – by determining the proportion of invaded cells that
were transfected (or ‘IX/I’) - showed a trend toward decreased
invasion, although this was not statistically different from the
scrambled control (Figure 8A, gray bars; P=0.097); however, upon
normalizing the data for transfection efficiency (i.e. the number of
invading, transfected cells over the total number of transfected
cells, or ‘IX/X’), there was indeed a statistically significant
(P,0.05) inhibition of invasion caused by disruption of RI
anchoring (Figure 8B, gray bars). Thus, as demonstrated for
migration, PKA activity as well as type-I and type-II PKA
anchoring are required for the invasion of SKOV-3 cells into a
three-dimensional ECM.
Discussion
Over-expression of various PKA subunits is a hallmark of a vast
array of human tumors [47,48,49]), including ovarian cancer
[26,27,28], and often correlates with more severe pathology and
poorer prognosis. In this regard, PKA is classically thought to
enhance mitogenic signal transduction and promote early cell
cycle transition. However, a number of reports have also
established a role for PKA in promoting invasion and metastasis
in a number of tumor models [50,51,52,53,54]; however, this line
of investigation has not been extended to EOC until now. Our
results clearly demonstrate that spatial regulation of PKA activity
is a critically important facet of the migration and invasion – and
thus, perhaps the metastasis – of EOC cells.
Previous work has demonstrated enrichment of PKA in the
leading edge of migrating cells, with the most detailed descriptions
being in fibroblasts [13,21] and breast and colon carcinoma cells
[22]. Our data now extends this paradigm to EOC cells and
expands the paradigm in an important and substantive way by
demonstrating localization of PKA to the leading edge during
three-dimensional matrix invasion. Furthermore, we have also
demonstrated the requirement for AKAP function for the
migration of EOC cells, as has been demonstrated for other cell
types [13,39,55]. Finally, we have also demonstrated – for the first
time - the requirement for PKA anchoring via AKAPs for cancer
cell invasion of a three-dimensional ECM. A number of previous
reports have implicated a variety of AKAPs as positive or negative
regulators of invasion and metastasis: these include AKAP9/yotiao
[56]; AKAP12/SSeCKS/gravin [57,58]; AKAP13/AKAP-Lbc
[59]; the erzin/radixin/moesin and merlin protein family
[60,61,62]; and the WAVE (Wiskott-Aldrich syndrome/verpolin-
homologous) -1 and 2 proteins [63,64]. Without exception,
however, those reports dealt with gain- or loss-of-function of their
respective AKAPs as a whole and did not specifically target only
the PKA anchoring domain. This is an important corollary, as the
overwhelming majority of known AKAPs – and essentially all of
those previously implicated in metastasis – have important
functions beyond their ability to anchor PKA [19,20]. Thus,
complete gain- or loss-of-function studies, i.e. over-expression or
silencing of an entire AKAP, would affect all of its potential
functions. In many cases, the functions other than PKA anchoring
are quite powerful – e.g. guanine nucleotide exchange for Rho
family GTPases (AKAP-Lbc/AKAP13); scaffolding other kinases
and enzymes (AKAP9, AKAP12); coupling membrane receptors
to the cortical actin cytoskeleton (ezrin family proteins); dendritic
actin nucleation (WAVE1 and 2) – and could readily contribute to
invasion and metastasis in their own right. In the current study,
however, we specifically inhibited only the ability of AKAPs to
anchor PKA; thus, to our knowledge, ours is the first report to
establish a role specifically for PKA anchoring per se in events
related to metastasis.
An important question arises from the current observations: if
leading edge PKA activity is mediated by exclusively by RII-
AKAP interactions, as reported here, then why are both type-I
and type-II PKA anchoring required for migration and invasion?
This question is, at the same time, both reassuring and vexing, as
both type-I and II PKA have been previously implicated in cell
migration [13,21,22,39], but it is becoming increasingly clear that
the two types of PKA have non-overlapping targets and functions
Figure 6. PKA is activated at the leading edge of invading
SKOV-3 cells. (A-D) SKOV-3 cells transiently expressing pmAKAR3
were subject to the donut invasion assay and images of cells on the
monolayer periphery were acquired 10 h after gasket removal.
Pseudocolored FRET images are shown, with insets depicting enlarge-
ments of the areas indicated by the white rectangles in each panel.
White arrows indicate the direction of invasion with respect to the cell
monolayer. Scale bar =10 mm. (E, F) To quantify the number of
invading cells exhibiting leading edge PKA activity, the average FRET
ratio was measured by linescan in the leading edge (LE) and the
cytoplasm (Cyto) of cells and a ratio of these values (FRET(LE/Cyto)) was
determined. (F) shows the percentage of cells exhibiting low, medium,
or high LE/Cyto FRET ratios, as described in Figure 4 (n=28 from four
separate experiments).
doi:10.1371/journal.pone.0026552.g006
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pmAKAR3, a membrane-tethered biosensor for measuring PKA
activity, which – by design – does not faithfully report any cytosolic
PKA activity that may exist some distance from the membrane.
Thus, it is possible that there may be some leading edge PKA
activity, within the thin layer of cytoplasm that is distant from the
membrane, that is attributable to RI-AKAP interactions. Perhaps
more likely is that, during migration, there is significant PKA
activity within the cytosol that is both not detected by the
membrane-tethered pmAKAR3 and not as ‘concentrated’ (in
terms of specific PKA activity per total cellular protein) as the
activity within the leading edge [13,21,22,39]]. Thus, while RII-
AKAP complexes preferentially regulate events within the leading
edge, RI-AKAP complexes may preside over myriad events within
the rest of the cell – outside the leading edge – that also ultimately
contribute to migration/invasion. Delineating the precise deficits
in migration and invasion associated with type-I and type-II PKA
would best require a complete catalog of the specific molecular
targets for each type of PKA activity and an understanding of what
role each target plays in migration/invasion; at present, this is
quite unfeasible. More reasonably, however, one could begin to
empirically address the matter through more frequent imaging and
closer correlation of cell morphology and PKA activity over the
entire duration of migration and invasion, and subsequent
observation of discrete changes in these parameters in the absence
of type-I or type-II anchoring.
While we have clearly demonstrated that PKA and AKAP
function are both required for EOC cell migration and invasion,
the discrete molecular targets for PKA as well as the specific
AKAP(s) responsible for PKA localization in these cells are
unknown. Delineation of specific signaling pathways that link PKA
to migration and invasion is made difficult by the considerable and
growing number of cytoskeleton- and/or migration-associated
PKA substrates [16,23] and anchoring proteins [19,20,24]. It is
Figure 7. Invading edge PKA activity is mediated by RII-AKAP interactions. (A-D) SKOV-3 cells co-expressing the indicated plasmids in
conjunction with pmAKAR3 were subject to the donut invasion assay for 18 hr and imaged via FRET microscopy. Representative pseudocolored FRET
images of cells co-expressing mCherry fused to (A) scrambled superAKAPis (sAKAPis scr), (B) superAKAPis (sAKAPis), (C) scrambled RIAD (RIAD scr), or
(D) RIAD are shown. White arrowheads point to leading edge PKA activity (scale bar =10 mm). (E) The results, as the percentages of cells exhibiting
PKA activity at the invasive edge (I.E.), were tabulated as in Figure 4 (n=21 from three separate experiments).
doi:10.1371/journal.pone.0026552.g007
Figure 8. PKA activity and anchoring are required for SKOV-3 cell invasion. (A, B) SKOV-3 cells were transiently transfected with plasmids
to inhibit PKA activity or anchoring (mCh-PKI, GFP-RIAD, GFP-sAis) or their respective controls (Empty mCh, GFP-RIAD_scr, GFP-sAis_scr), then subject
to invasion analysis as described in Figures 3 and 4. (*=P,0.01; **=P,0.05). In parallel to the method described in Figure 3, invasion was calculated
as the average percentage (6 S.E.) of invading transfected cells over the total number of invading cells (A; ‘IX/I’) or, to normalize for transfection
efficiency, the average percentage of invading transfected cells over the total number of transfected cells (B; ‘IX/X’).
doi:10.1371/journal.pone.0026552.g008
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of either type-I or type-II PKA anchoring blocks migration and
invasion, likely through different effectors. Furthermore, while not
the focus of the current study, it should be noted that, as a kinase
regulated by intracellular cAMP, PKA is quite likely to work in
concert with the other major cAMP effectors, the Epacs (exchange
proteins activated by cAMP), which can form multi-component
scaffolds with PKA to mediate signaling events in response to
cAMP [66,67] and also have considerable influence over cell
adhesion, migration and related events [68,69]. This possibility
notwithstanding, the current study unequivocally establishes a role
for PKA itself, in a paradigm involving its localization through
AKAPs, in the regulation of ovarian cancer migration and matrix
invasion.
While our data demonstrate the necessity for PKA activity and
anchoring during migration as well as invasion, it is not known
whether the targets for PKA during migration will be the same as
those in invasion. Although the processes are intimately related,
migration can occur without invasion, but invasion cannot occur
without migration, and the exact mechanism of migration during
invasion may differ as a function of cellular phenotype and
microenvironmental cues [64-67]. Given our growing apprecia-
tion of the differences between cell migration in two-dimensions vs
three-dimensions [41,42] and the differences between normal and
tumor cell migration [43,44], it would not be surprising if distinct
(but, likely, somewhat overlapping) sets of PKA substrates and
anchoring proteins were called upon to specifically regulate the
processes involved in EOC cell invasion compared to migration.
An intriguing example would be a requirement for localized PKA
in regulating the expression, secretion or function of ‘invasion-
specific’ proteins such as matrix metalloproteases [52]. Nonethe-
less, the identification of the substrates and anchoring proteins for
PKA that are relevant to migration and invasion are an ongoing
focus for several laboratories, including our own. Indeed,
propitious initial candidates for relevant AKAPs would be those
that appear to be up-regulated in various forms of EOC AKAP3/
AKAP110 [29,30]; AKAP1/AKAP149 and AKAP13/AKAP-Lbc
(A.K. Howe, unpublished observations)).
Although it only accounts for approximately 3% of all cancer
diagnoses in the United States, ovarian cancer is the 5
th leading
cause of death among women [1]. This is largely due to the fact
that most ovarian cancer patients become symptomatic - and are
therefore diagnosed - after the tumor has metastasized. The
metastatic spread of EOC, like other cancers, is completely
dependent on the acquired ability of tumor cells to undergo
invasive cell migration [2]. In this work, we have shown that both
migrating and invading EOC cells exhibit enriched PKA within
their leading edge and that both PKA activity and its localization
through AKAPs are required for migration and invasion of EOC
cells. This is the first demonstration of an association of localized
PKA activity and the process of matrix invasion. More
importantly, these observations add important new molecular
insight into some of the most clinically relevant cellular behaviors
associated with the pathogenesis of EOC. To be certain, the in vitro
mode of matrix invasion assessed in the current study does not
recapitulate the full course and associated mechanisms of EOC
metastasis in vivo. Especially relevant in this regard are the complex
biology of both the interaction of metastatic EOC cells with their
target microenvironment, which consists of mesothelial cells and
fibroblasts in addition to ECM components [40,70], and of
multicellular tumor spheroids, regarded as the minimal metastatic
unit of EOC [71]. Nonetheless, the current studies provide a solid
foundation that justifies the further exploration of the role of PKA
and AKAP function in higher-order models of EOC metastasis.
Supporting Information
Figure S1 PKA activity and anchoring are required for
normal leading edge morphology in migrating SKOV-3
cells. (A-C) Confluent monolayers of SKOV-3 cells plated on
FN-coated coverslips were wounded by scratching and re-fed with
media containing DMSO (A, Ctrl), 10 mM H89 (B), or 50 mM
StHt31 (C). Cells were allowed to migrate into the wound for 4 h
before fixation and staining to visualize F-actin (green) and the
focal adhesion proteins VASP (red) and vinculin (blue). (D)
SKOV-3 cell monolayers were cultured and wounded as described
above, then treated with DMSO (Ctrl), H89, StHt31, or 25 mM
mPKI. After 4 h, the cells were fixed and stained as above and the
number of leading edge lamellipodia in cells at the wound edge
was quantified. Values represent the means 6 S.E. from at least
three experiments (n.100; *=P,0.001).
(TIF)
Figure S2 The donut migration assay preserves ECM
protein coating better than scratch assays. (A) COS-7 cells
were plated on coverslips coated with 20 mg/ml FN and subject to
either the donut migration assay or a scratch migration assay for
2 hrs. Coverslips were fixed and processed for immunofluores-
cence using an antibody against FN, fluorescent phalloidin to
stain F-actin, and DAPI to stain nuclei, then examined by
fluorescent microscopy. White arrows depict regions used for
linescan analysis. (B) Linescan analysis, showing the relative
intensity (arbitrary units) of FN fluorescence, of the regions
depicted in (A). (C) The bar graph represents the average 6 S.E.
of the percent FN preserved at the assay front from multiple
linescans across three separate donut and scratch migration assays
(*=P,0.001).
(TIF)
Figure S3 The donut migration assay preserves cell
viability on the assay periphery. (A) COS-7 cells were plated
on FN-coated coverslips and subject to either donut or scratch
migration assays. The panels depict phase contrast images of
representative fields along the periphery of both assays after
staining with trypan blue immediately after donut removal or
wounding of the monolayer. (B) The data represent the average 6
S.E. number of cells that retained the trypan blue stain per 10x
field on the assay periphery (*=P,0.001).
(TIF)
Figure S4 RII, but not RI, PKA subunits are enriched at
the leading edge of migrating SKOV-3 cells. Representative
immunofluorescent images of SKOV-3 cells plated on fibronectin
(10 mg/ml) coated coverslips for 3 h, then fixed and stained with
the antibodies against RI (red) and RII (green) subunits, and with
fluorescent phalloidin to stain filamentous actin (blue) are shown.
Linescan analysis was used to determine the fluorescence intensity
of each target at the leading edge (L.E.) versus the nearby
cytoplasm (Cyto) and the average ratio (-/+ std. dev.) of these
values for 12 separate linescans was calculated.
(TIF)
Figure S5 Biosensor activity of pmAKAR3 is PKA-
specific. SKOV-3 cells were transfected with plasmid expressing
pmAKAR3 alone or co-transfected with plasmids expressing
pmAKAR3 and pmCherry-PKI and, 24 h later, were subjected to
the donut invasion assay as described for Figures 5 and 6. FRET
ratio images were taken of cells along the perimeter of the
monolayer 8 h after the start of the assay. The direction of
invasion is indicated by the white arrow.
(TIF)
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ImageJ.
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Movie S1 PKA is activated at the leading edge of
migrating SKOV3 cells.
(AVI)
Table S1 Primers used to generate pEGFP-superAKA-
Pis, RIAD, and their scrambled controls.
(DOC)
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